PCM
PRME icon

Polymer Capital Management’s Prime Medicine PRME Stock Holding History

Polymer Capital Management’s Portfolio PRME Stock Details PRME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$35.9K Sell
10,317
-25,664
-71% -$97.7K ﹤0.01% 801
2025
Q4 		$125K Buy
35,981
+15,190
+73% +$67.6K 0.01% 720
2025
Q3 		$115K Buy
+20,791
New +$84.5K 0.01% 724

Other funds holding PRME

AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Polymer Capital Management's PRME Position: Q1 2026 in Review

Polymer Capital Management reduced its Prime Medicine (PRME) stake by 71% in Q1 2026, selling an estimated $97.7K and leaving 10,317 shares worth $35.9K. The position accounts for ﹤0.01% of the portfolio, ranked #801.

Polymer Capital Management first reported a position in PRME in Q3 2025 and has held it in 3 quarters since. The position peaked at $125K in Q4 2025. 192 funds tracked by Wall St. Rank hold PRME as of Q1 2026.

  • Polymer Capital Management held 10,317 shares of Prime Medicine worth $35.9K as of Q1 2026.
  • Polymer Capital Management sold 25,664 Prime Medicine shares in Q1 2026, an estimated $97.7K.
  • Prime Medicine made up ﹤0.01% of Polymer Capital Management's portfolio in Q1 2026, its #801 holding.
  • Polymer Capital Management first reported a position in Prime Medicine in Q3 2025 and has held it in 3 quarters since.
  • Polymer Capital Management's Prime Medicine position peaked at $125K in Q4 2025.
  • 192 funds tracked by Wall St. Rank held Prime Medicine as of Q1 2026.

Based on Polymer Capital Management's 13F filing for Q1 2026, filed 14 May 2026.